Issued U.S. patent strengthens IP for Allon technology platform
Gordon McCauley, President and CEO of Allon, said the new peptides have demonstrated neuroprotection characteristics in preclinical studies by protecting against neuronal cell death after exposure to the potent neurotoxin tetrodotoxin.
“These new peptides are additional pipeline candidates from our proprietary ADNF technology platform and distinct from our lead ADNF product candidate AL-309” said McCauley. “We are encouraged that the capacity of our platform technologies to generate multiple product candidates has again been validated by the issuance of these patents.”
Most read news
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.